• OSI Pharmaceuticals Inc., of Melville, N.Y., reported worldwide net sales of Tarceva (erlotinib) of $226 million for the third quarter, representing a 32 percent growth in global sales compared to the same period in 2006. Tarceva is partnered with South San Francisco-based Genentech Inc. and Basel, Switzerland-based F. Hoffmann-La Roche Ltd. OSI reported total revenues of $100 million for the three months ending Sept. 30, 2007, and posted net income, comprised of its continuing operations and discontinued ophthalmic operations, of $29.6 million, or 49 cents per share. OSI ended the quarter with $291.1 million in cash and investments. Those solid earnings boosted OSI stock (NASDAQ:OSIP) $5.05 Friday to close at $41.71,
To read more on related topics, click on one of the words below.